AX-2026-041754

Selank · 20 mg declared · Thermo Fisher Scientific (China) Co., Ltd. · lot TFS-{CAT}-1712

PASSIDENTITY CONSISTENT

Report ID: AX-2026-041754
Compound: Selank
Compound class: Neuroactive and cognitive peptides
Supplier: TFS — Thermo Fisher Scientific (China) Co., Ltd.
Batch / lot: TFS-{CAT}-1712
Declared label claim: 20mg
Laboratory: PeptideMeter
Assay date: 23 Apr 2026
Submitted: 06 May 2026
Quarter: 2026-Q2
Submitter: l.lokken
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	99.93	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.07	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — diketopiperazine (−18 Da)	0.05	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	751.4402	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	751.4395	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-0.9	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	7.49	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.08	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.39	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.42	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	6.16	min	6.03 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.06	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	72,786	—	≥ 20,000	PASS
Resolution to nearest impurity	vs diketopiperazine (−18 Da)	1.79	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 72,786, and skew follows the reported asymmetry factor of 1.06. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.05 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Selank — main peak	6.16	4,856,908	99.93	—
2	diketopiperazine (−18 Da)	6.33	2,430	0.05	-18.011
3	tuftsin fragment (−417 Da)	5.58	972	0.02	-417.235
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 751.4402 Da, computed from C33H57N11O9. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 751.4395 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	376.7274	376.7270	-0.0004	60.0
1+	752.4475	752.4468	-0.0007	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.93	divergence +0.03 pp vs batch median
Total impurities (% area)	0.10	0.07
Largest single impurity (% area)	0.06	0.05
Water (%)	7.0	7.49
Counter-ion (%)	4.3	5.08
Peptide content (%w/w)	88.1	not determined
Endotoxin (EU/mg)	0.14	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 18 d) → laboratory (courier, dry ice, 8 d) → assay.
Assay date: 23 Apr 2026
Submitted to the index: 06 May 2026
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

esi_tof06 May 2026

Identity confirmed, purity 99.93 %, mass balance closed. This record is complete against the index definition of complete and there is nothing outstanding on it.

quad_unit06 May 2026

The index grades identity by instrument class, not by the ppm figure alone: "confirmed" where the determination was made at high resolution, "consistent with" where it was not. The status block above says which applies to this record, and it is worth reading before the number.

lot_traceability06 May 2026

Lot TFS-{CAT}-1712 on the vial matches the certificate that came with it. That is the check every buyer can do in ten seconds and most do not.

Section 7

Related records

Same batch — lot TFS-{CAT}-1712 n=13

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041751	TFS-{CAT}-1712	Janoshik	2026-Q2	99.76	8.19	89.9	Buyer-sourced	2	MARGINAL
AX-2026-041752	TFS-{CAT}-1712	Medutest	2026-Q2	99.63	7.43	—	Buyer-sourced	1	FAIL
AX-2026-041753	TFS-{CAT}-1712	Janoshik	2026-Q2	99.67	7.48	92.6	Buyer-sourced	0	PASS
AX-2026-041755	TFS-{CAT}-1712	VendorInvestigate	2026-Q2	99.93	7.37	104.5	Buyer-sourced	0	PASS
AX-2026-041756	TFS-{CAT}-1712	PeptideMeter	2026-Q2	99.90	8.21	103.7	Buyer-sourced	0	PASS
AX-2026-041757	TFS-{CAT}-1712	Medutest	2026-Q2	99.93	7.54	—	Buyer-sourced	0	PASS
AX-2026-041758	TFS-{CAT}-1712	Janoshik	2026-Q2	99.78	8.10	97.6	Buyer-sourced	0	PASS
AX-2026-041759	TFS-{CAT}-1712	Janoshik	2026-Q2	99.93	8.13	102.2	Buyer-sourced	0	PASS
AX-2026-041760	TFS-{CAT}-1712	Janoshik	2026-Q2	99.82	7.70	—	Buyer-sourced	0	PASS
AX-2026-041761	TFS-{CAT}-1712	PeptideMeter	2026-Q2	99.93	7.79	91.8	Buyer-sourced	0	PASS
AX-2026-041762	TFS-{CAT}-1712	Janoshik	2026-Q2	99.75	7.24	—	Buyer-sourced	0	PASS
AX-2026-041763	TFS-{CAT}-1712	PeptideMeter	2026-Q2	99.87	8.20	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Selank records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042858	GGPeps	GGPE-2603-J2447	VendorInvestigate	2026-Q3	98.87	8.85	99.4	Buyer-sourced	0	FAIL
AX-2026-042859	GGPeps	GGPE-2603-J2447	PeptideMeter	2026-Q3	98.92	9.48	103.5	Buyer-sourced	0	FAIL
AX-2026-041759	TFS	TFS-{CAT}-1712	Janoshik	2026-Q2	99.93	8.13	102.2	Buyer-sourced	0	PASS
AX-2026-042912	GGPeps	GGPE-2601-J3130	Janoshik	2026-Q2	99.75	9.44	89.7	Buyer-sourced	1	MARGINAL
AX-2026-041760	TFS	TFS-{CAT}-1712	Janoshik	2026-Q2	99.82	7.70	—	Buyer-sourced	0	PASS
AX-2026-041752	TFS	TFS-{CAT}-1712	Medutest	2026-Q2	99.63	7.43	—	Buyer-sourced	1	FAIL
AX-2026-042915	GGPeps	GGPE-2601-J3130	PeptideMeter	2026-Q2	99.53	10.03	—	Buyer-sourced	0	PASS
AX-2026-042910	GGPeps	GGPE-2601-J3130	VendorInvestigate	2026-Q2	99.62	9.21	105.0	Buyer-sourced	0	PASS

Other recent TFS records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041681	CJC-1295 with DAC	TFS-{CAT}-9675	PeptideMeter	2026-Q3	98.82	3.67	—	Buyer-sourced	0	PASS
AX-2026-041766	BPC-157	TFS-{CAT}-1156	Janoshik	2026-Q3	99.54	6.34	—	Buyer-sourced	1	MARGINAL
AX-2026-041682	CJC-1295 with DAC	TFS-{CAT}-9675	Nordanalyt	2026-Q3	98.94	3.24	—	Buyer-sourced	0	PASS
AX-2026-041683	CJC-1295 with DAC	TFS-{CAT}-9675	Medutest	2026-Q3	98.68	3.46	97.0	Buyer-sourced	0	PASS
AX-2026-041765	BPC-157	TFS-{CAT}-1156	Janoshik	2026-Q3	99.79	6.01	—	Buyer-sourced	0	PASS
AX-2026-041680	CJC-1295 with DAC	TFS-{CAT}-9675	Medutest	2026-Q3	99.18	2.85	100.4	Buyer-sourced	0	PASS
AX-2026-041691	Semaglutide	TFS-{CAT}-9744	Janoshik	2026-Q2	98.31	6.07	91.4	Buyer-sourced	0	PASS
AX-2026-041700	SS-31 (Elamipretide)	TFS-{CAT}-1142	Medutest	2026-Q2	99.75	2.27	96.3	Buyer-sourced	0	PASS